# Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

> **NCT02095717** · PHASE2 · TERMINATED · sponsor: **Centre Jean Perrin** · enrollment: 50 (actual)

## Conditions studied

- Prostate Cancer Metastatic Castration Resistant

## Interventions

- **DRUG:** Curcumin
- **DRUG:** Placebo
- **DRUG:** Taxotere

## Key facts

- **NCT ID:** NCT02095717
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** The trial was stopped for futility in view of the results of the interim analysis
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095717, "Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02095717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*